Recall of Musclepharm Assault Hybrid Series Supplement Due to the Presence of Elevated Levels of Nicotinic Acid
Friday, 22 April 2016
| Summary | |
|---|---|
| Category 1: | For Action |
| Alert Notification: | 2016.14 |
| Product: |
Musclepharm Assault, The Athletes Pre-Workout System, Hybrid Series; all flavours, all pack sizes |
| Batch Code: | All batches |
| Country Of Origin: | United States |
Message:
Musclepharm has confirmed to the FSAI that all flavours of the above product contain 25 mg / serving of niacin, in the form of nicotinic acid. Consuming this product may present a risk to health as the tolerable upper intake level for nicotinic acid is 10 mg/day, according to the European Food Safety Authority (EFSA).
Nature Of Danger:
Consuming nicotinic acid at levels greater than 10 mg per day may cause vasodilation and flushing, leading to hypotensive episodes (low blood pressure).
Action Required:
Inspectors:
Environmental health officers (EHOs) are requested, as part of routine inspections, to check businesses to determine if the affected supplement is on sale. If found, EHOs should oversee a recall of the implicated product and ensure point of sale notices are displayed. Please notify the FSAI (rapidalert@fsai.ie) of the name and address of any suppliers of this product.
Manufacturers, wholesalers, distributors, caterers & retailers:
Businesses that have sold the implicated supplement directly to consumers must place a point of sale recall notice in store and/or on their website to inform their customers not to consume the supplement. Food business operators should inform their local EHO.
Consumers:
Consumers are advised not to consume the implicated supplement. Anyone who has consumed this supplement and is feeling unwell should seek medical advice.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
